- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02276508
Open Label Trial of Nissle 1917
Phase 1 Open Label Trial of Nissle 1917 to Assess Safety and Tolerance in Healthy Adult Volunteers
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Nissle 1917 is an E. coli based probiotic that has been successfully used in Europe for close to 100 years to treat largely gastrointestinal disorders like inflammatory bowel disease, gastroenteritis, and irritable bowel syndrome. In addition to those disorders, we believe that Nissle 1917 is a promising alternative therapy for prevention of urinary tract infections in susceptible individuals.
Purpose: The Phase 1 trial will use Nissle 1917 in healthy adult patient volunteers for the first time in the United States. The investigators will track the frequency and incidence of side effects and adverse events.
Participants:
20 adult (>21 years of age) healthy volunteers
Protocol:
- Participants will enroll in our trial after a review of medical history and physical.
- Participants will then take 30 day course of Nissle 1917 capsules
- Investigators will telephone participants 1-2 weeks after they have begun the trial to assess for any side effects or adverse events
- Subjects will also be provided with a diary to record any side effects or adverse events
- At the end of 30 days, participants will return to clinic for a follow up visit to discuss any side effects or adverse events experienced during the trial and to return any unused medication
- Investigators will again telephone all participants 28-35 days following completion of the study drug again to pose a questionnaire aimed at revealing any side effects or adverse events.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43205
- Nationwide Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy adult volunteer of age 21 years or older
Exclusion Criteria:
- Any individual with an active urinary tract infection (UTI)
- Any individual with an acute illness within the past 7 days
- Any individual with neurogenic bladder or with vesicoureteral reflux
- Any individual with any anatomic abnormality, congenital or acquired, of the urinary tract system
- Any individual with any anatomic abnormality, congenital or acquired, of the gastrointestinal tract
- Any individual with untreated dysfunctional elimination syndrome
- Immunocompromised patients
- Individuals with a central venous catheter
- Individuals requiring the use of antibiotics, immunomodulatory medications, or other probiotics
- Any participant with a history of chronic gastrointestinal disease
- Any individual with a chronic uncontrolled medical illness
- Any female of reproductive age who is currently pregnant, breastfeeding, or sexually active and unwilling or unable to use an acceptable method of contraception.
- Any participant is unable to appropriately take and store medication
- Any individual enrolled in a clinical trial evaluating another investigational agent in the last 30 days.
Study Plan
How is the study designed?
Design Details
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Probiotic
Participants will take the E. coli Nissle 1917 as an orally administered medication first while in clinic to be observed for 30 minutes for any hypersensitivity reaction.
The dose of Nissle 1917 will be 100mg capsule (2.5-25x109 organism) once daily for a total of 4 days.
Participants will then increase the dose to 2 capsules (200mg) once daily for the remaining 26 days of the study period.
|
Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of adverse events associated with ingestion of E. coli Nissle 1917
Time Frame: 30 days
|
30 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Venkata R Jayanthi, MD, Nationwide Children's Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB14-00586
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Urinary Tract Infections
-
GlaxoSmithKlineCompletedInfections, Urinary TractEgypt
-
University of WashingtonNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Iterum Therapeutics, International LimitedCompletedComplicated Urinary Tract InfectionsUnited States, Estonia, Hungary, Georgia, Latvia
-
Shandong Branden Med.Device Co.,LtdTerminatedUrinary Tract Infection | Urinary CathetersChina
-
Inmunotek S.L.CompletedUrinary Tract Infection BacterialSpain, United Kingdom
-
AbbottCompletedUrinary Tract Infections (UTIs)Pakistan
-
Newcastle-upon-Tyne Hospitals NHS TrustCambridge University Hospitals NHS Foundation Trust; University of Southampton and other collaboratorsCompletedUrinary Tract Infections, RecurrentUnited Kingdom
-
Hospital del Río HortegaCompletedUrinary Tract Infection
-
Assaf-Harofeh Medical CenterNanovibronixUnknown
-
Bergaliden BarnavårdscentralCompleted
Clinical Trials on E. coli Nissle 1917
-
Keimyung University Dongsan Medical CenterCompletedConstipationKorea, Republic of
-
Ardeypharm GmbHICON plc; Clinscience Sp. z o.o.Completed
-
University of ZurichUnknownEscherichia Coli InfectionsSwitzerland
-
Kangbuk Samsung HospitalCompletedUlcerative ColitisKorea, Republic of
-
Erasmo SpazianiRecruiting
-
Nationwide Children's HospitalThrasher Research FundCompletedCatheter-Related Infections | Recurrent UTIsUnited States
-
GWT-TUD GmbHArdeypharm GmbHCompletedDiabetes Mellitus Type IIGermany
-
Max NieuwdorpNot yet recruiting
-
University of HohenheimArdeypharm GmbHCompleted
-
University of OuluTurku University Hospital; Helsinki University Central Hospital; Kuopio University... and other collaboratorsRecruitingUrinary Tract Infections in Children | Secondary PreventionFinland